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What is non-alcoholic fatty liver disease? 
Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease in western 
society [1-5]. NAFLD occurs when fat progressively invades the liver parenchyma (figure 1a 
and 1b). The hepatocytes are saturated with microscopically visible fat (macro-vesicular), 
causing displacement of the cell nucleus to the edge of the cell. The bulk of these lipid-laden 
cells eventually cause hepatomegaly. The American Association for the Study of Liver 
Diseases (AASLD), states that the normal content of liver fat is 5% of the weight of the liver 
[6]. NAFLD is defined as fat accumulation in the liver exceeding 5% by weight. NAFLD 
represents a spectrum of changes, from simple steatosis (fat only changes), steatohepatitis 
(NASH) (fat and inflammation), NASH plus fibrosis, to cirrhosis (replacement of liver 
parenchyma by scarred, fibrotic non-functioning tissue) and hepatoma [5]. It may occur in 
patients that do not consume alcohol in amounts known to be harmful [7]. 
Fig 1a. Histology of a normal liver, compared to 1b., a fatty liver. 
Aetiology 
NAFLD is subdivided into primary and secondary types [1]. Primary NAFLD is common in 
morbidities such as obesity, type 2 diabetes and metabolic syndrome. Insulin resistance (IR) 
is associated with these conditions. Secondary NAFLD can be associated with the use of 
medications, as well as disorders relating to infection, and nutritional and metabolic 
conditions that can occur with inborn errors of metabolism [1]. 
Metabolic syndrome 
NAFLD is associated with metabolic syndrome (MS), a condition which is categorised by 
increased IR. NAFLD is thought to be the hepatic representation [8, 9]. Those with NAFLD 
are predisposed to atherosclerosis and cardiovascular disease and have an increased risk of 
death [10,11]. There is an association between MS and polycystic ovary syndrome [ 12 ]. 
IR refers to the body’s inability to utilise glucose for energy. The insulin is presented to the 
cell wall but the cell wall receptors are unable to receive glucose. The pancreas then produces 
more insulin, but the glucose is still unable to be utilised. This process continues until the 
pancreas fails, resulting in type 2 diabetes mellitus. 
Obesity leads to insulin resistance which in turn leads to NAFLD. IR is a precursor to 
diabetes and up to 75% of diabetic patients have NAFLD [8]. 
Why is NAFLD a problem? 
NAFLD affects the liver, but more importantly, it is an indicator of systemic disease due to 
MS. The extent of this condition causes an increase in mortality and morbidity that consumes 
a disproportionately high percentage of available health resources [ 13 ].  
Pathophysiology: How does fat get to the liver? 
There are three mechanisms by which fat is delivered to the liver. 
1. By excessive intake of dietary fats and/or sugars. This leads to increased 
transport of fats via the portal system to the liver. The excessive amounts of 
fats are ultimately stored in the hepatocytes. 
2. Through breakdown of adipose tissue. People with excess adipose tissue have 
excessive fatty acids in the circulatory system and these fats are also stored in 
the liver parenchyma. 
3. De novo. By synthesis of food as it is broken down. Food must be digested so 
that it can be assimilated into the blood stream and tissues to provide energy 
for vital activities and functions. The metabolites produced in this process may 
be synthesised into lipids. The factors driving the biochemical pathways 
concerned with this synthesis are areas actively researched. Many people with 
fatty liver disease have high to very high iron levels. Iron is an element that is 
crucial in the normal function of the body. It is concerned with oxidation-
reduction reactions. The body absorbs dietary iron through the duodenum and 
stores it in the heart, liver and pancreas. Multiple proteins are involved in iron 
uptake and storage. The exact role that each protein plays in the process is 
unknown [4]. 
Brunt commented “The interplays between NASH and abnormal iron indices, hepatocellular 
iron overload, and mutations of the HFE gene are areas of active investigation and debate in 
the literature.” [14]. 
The first two mechanisms of the pathological process are amenable to intervention such as 
diet and exercise. Until the mechanisms of pathology are better understood, the de novo stage 
is considered innate and little can be done to change outcomes.  
Pathogenesis. How does fat cause damage? 
• Liver Disease  
The laying down of fat within the hepatocytes can lead to progressive liver disease. This form 
of NAFLD can ultimately lead to cirrhosis, liver failure and hepatoma. NAFLD is thought to 
be responsible for cryptogenic cirrhosis (not associated with hepatitis B and C). 
Why does simple liver disease progress from simple NAFLD to NASH? 
The mechanism of damage is thought to result from the so-called ‘second hit theory’. 
‘Something’ happens to turn ‘simple’ steatosis to NASH. The first insult to the liver is the 
laying down of fat within the cells, and then a second insult occurs to further damage the 
hepatocytes and cause irreparable and progressive damage. This second insult may be the 
result of hypoxia of the liver as occurs with sleep apnoea or gut flora enzymes. Enzymes 
produced by some types of gut flora; e.g. Helicobacter pylori, are thought to be similar to the 
by-products of alcohol consumption and therefore result in similar damage to the liver [15, 
16]. 
Kashi et al., describe the pathogenesis of NAFLD as a two -step cyclical problem: 
Hyperinsulinemia and leptin resistance cause the accumulation of fat in the hepatocytes 
resulting in “unregulated hepatic de novo lipogensis, increased fatty acid oxidation and 
decreased export of hepatic triglycerides in the form of very low density lipoprotein.” [3]. 
If a second insult occurs to the liver involving oxidative stress, the fat molecule undergoes 
peroxidation, making it unstable, which allows it to react with and cause the production of 
proinflammatory cytokines, leading to subsequent inflammation and fibrosis of the cells. 
Currently there is no imaging technique that can distinguish between simple NAFLD and 
NASH, therefore this diagnosis is dependent entirely on histological evidence. 
• Cardiovascular disease (CVD) 
Until recently the association of NAFLD with CVD has been less publicised; however, this 
connection is more significant than localised liver disease. A person with NAFLD is more 
likely to die of heart disease than liver disease [1,17]. There is significant morbidity 
associated with cardiovascular disease. By early diagnosis for prevention and/or treatment of 
NAFLD, improved patient outcomes can be expected.  
Prevalence 
NAFLD is extremely common. A study, using proton Magnetic Resonance Spectroscopy, to 
measure hepatic triglyceride content, determined that the prevalence of hepatic steatosis 
(where fat content was greater than 5.5% by weight) in the United States, was 31%  [18]. 
Other studies estimated that approximately 75% of obese patients have NAFLD and in 
addition, 20% have NASH [19]. 
In the paediatric population, NAFLD is recognized as a common and increasing form of liver 
disease [11,20]. Using raised alanine aminotransferase (ALT) as an indicator, Australian data 
suggests 10% of 15 year olds in New South Wales have NAFLD [21]. 
NAFLD can be found in all age groups, but the prevalence appears to increase with age. Data 
based on liver biopsies obtained following fatal traffic causalities in Scandinavia in 1977, 
show the prevalence for fatty liver to be 1% in people below 20 years of age, 18% between 
20-40 years, and 39% among those 69 and older [1]. 
Studies have shown that patients with obstructive sleep apnoea (OSA) have a higher 
prevalence of NAFLD [22,23].  This association is partly related to increased body mass 
index and IR in this group, although OSA is thought to be an independent risk factor for 
hepatic injury through hypoxia. 
The increasing prevalence of NAFLD across all spectrums of western society is thought to be 
directly related to widespread proliferation of calorie-intense food consumption and a 
decrease in physical activity. 
Clinical signs and symptoms 
NAFLD is generally asymptomatic, but when clinical signs are present, the two most 
common symptoms are lethargy and right upper quadrant abdominal discomfort. Lethargy is 
thought to be a result of IR, while right upper quadrant abdominal discomfort may be related 
to stretching of the liver capsule because of the increasing size of the liver. 
Apart form obesity, there are no definitive clinical signs of NAFLD, therefore, imaging, 
blood tests and histology are required for diagnosis. 
How is NAFLD currently diagnosed? 
Liver function tests (LFTs), blood lipid profile, CT, MRI, liver biopsy and ultrasound all 
contribute in the diagnosis of NAFLD. 
• LFTs 
Increased liver fat is associated with increased levels of aminotransfersases as seen on liver 
function tests. The three main tests used to evaluate liver function are alanine 
aminotransferase (ALT), aspartate aminotransferase (AST) and gamma glutamyl 
transpeptidase (GGT) [ 24 ]. 
ALT is an enzyme involved in the metabolism of alanine and aids in processing proteins. 
Increased ALT correlates well with increased liver fat on MRI, but it is non-specific. 
Increased ALT also occurs with viruses, infections, obstructive jaundice and myocardial 
infarction. 
AST is found in high concentration in liver cells and is also present in heart muscle and 
skeletal tissues. Very high levels of AST imply cell injury anywhere in the body. Large 
increases of AST occur with obstructive jaundice. 
The ratio between AST/ALT is used as a measure of cirrhosis, (not inflammation). 
A normal ratio of AST/ALT is 0.8. When the ratio is >2 this suggests alcohol excess. When 
the ratio is >1 but <2 this is indicative of NAFLD with cirrhosis. 
AST does not change until cell injury has occurred, therefore, inflammation without cirrhosis 
is not reflected in the AST levels. 
GGT facilitates the transport of amino acids across the cell membrane. Increased levels of 
GGT are usually indicative of increased alcohol intake, but if alcohol is excluded as a cause, 
the risk for CVD disease is increased three fold [17]. 
Liver fat identified on MRI correlates well with raised GGT levels. 
LFTs are non-specific and can be raised without liver disease such as occurs with some 
medications; e.g. erythromycin use, muscle disease and endocrine conditions. 
• Blood lipid profile 
High cholesterol is indicative of high quantities of circulating fats and is associated with high 
blood glucose levels. When a patient presents with raised fasting blood glucose, low HDL 
(high density lipoprotein), and elevated fasting triacylglycerols, they are likely to have 
NAFLD [4]. 
•  CT 
Liver fat content can be semi-quantitatively estimated by CT scans. A normal range is 50-75 
Hounsfield units. With increasing hepatic steatosis, the liver attenuation values decrease by 
1.6 Hounsfield units for every milligram of triglyceride deposited per gram of liver tissue. 
[25]. 
With CT, the diagnostic accuracy of differential changes in hepatic-splenic attenuation is 
time dependent and protocol specific. A non-enhanced hepatic CT scan remains the method 
used for the detection of a fatty liver [25]. When CT is compared directly with ultrasound, 
ultrasound is more sensitive at detecting fatty change, except when the changes are patchy or 
focal. 
• MRI 
MRI demonstrates liver fat by determining intensity differences between in- phase and 
opposite-phase images or images required with/without fat saturation. 
Proton magnetic resonance spectroscopy (H MRS), allows quantitative assessment of 
steatosis. This imaging method measures proton signals in hepatocyte triglyceride stores and 
has been shown to correlate closely with biochemical and histological assessment of liver 
triglyceride content. H MRS is largely a research tool with limited clinical application, 
whereas MRI is far more widely available, but expensive. The diagnostic gold standard for 
imaging is MRI [25, 26]. 
• Liver Biopsy 
The gold standard for diagnosis of NAFLD is liver biopsy [25, 26]. Liver biopsy is used to 
stage and grade NAFLD. However, on histology alone it is not possible to separate non-
alcoholic fatty liver disease from alcoholic fatty liver disease.  Therefore if cellular changes 
are present, patient history must be relied on to exclude alcohol intake before diagnosing 
NAFLD.  Liver biopsies are invasive, so for everyday purposes, NAFLD is commonly 
diagnosed by surrogate markers such as altered LFTs and imaging studies suggestive of 
hepatic steatosis. 
• Ultrasound 
Non-alcoholic fatty liver is diagnosed on ultrasound when there is: 
- increased echogenicity of the liver texture (when compared to the right kidney). 
- decreased penetration of sound identified by lack of transmission of sound  to the 
posterior diaphragm interface. 
- Lack of visibility of vascular structures within the liver due to ill-defined portal 
walls- these walls are invaded by fat so there is lack of definition between the 
portal wall and the surrounding liver tissue. There is no impedance mismatch 
between the two types of tissue, much like trying to find a green tree in a green 
forest, as compared to finding a red tree in a green forest. 
- increased liver size as measured in the mid clavicular line >15.5cm (figures 2a and 
2b). 
 
Fig 2a. Normal liver image. 2b. NAFLD. 
 
Traditionally, NAFLD diagnosed by ultrasound, has been rated as either mild, moderate or 
severe (infiltration) to coincide with the same histological categories:  
• Mild = 10-30% hepatocytes effected.  
• Moderate = 30-70% hepatocytes effected.  
• Severe =  >70% hepatocytes effected [9,14]. 
Ultrasound has been frequently criticised because of it wide inter and intra-observer error.   
Kappa coefficient for intra-observer error using ultrasound, have been stated as good; K value 
= 0.77 [25]. 
Kappa coefficient for inter-observer error using ultrasound has been stated as poor; K 
value=0.4-0.43 [25]. 
A Kappa value of 1 represents complete agreement. 
Further work needs to be conducted to standardize criteria on new equipment and to compare 
these results to modalities such as MRI, where concordance has been reported as good to 
excellent.  
Early fatty infiltration should have good inter and intra-concordance, but discrepancies may 
arise in differentiating moderate from severe infiltration. 
Ultrasound diagnosis of NAFLD in obesity (BMI>30) and morbid obesity (BMI >35), can be 
sub-optimal due to decreasing specificity and negative predictive values. The adiposity 
absorbs the sound, degrading the image and making diagnosis difficult. 
Future research 
Conventional and accepted methods of diagnosis have not been consistently correlated 
against each other and validated. Studies comparing different imaging modalities such as 
MRI and ultrasound are required. 
Prospective studies need to be conducted to demonstrate intra and inter-observer error of 
ultrasound using modern equipment, and to accurately document changes in liver texture 
following interventions, such as diet and exercise. 
If it is demonstrated that changes are present and are reversible, the true measure of effect can 
be ascertained. 
Conclusion 
Ultrasound can identify fat in the liver in the very early, ‘preclinical’ form of NAFLD. It can 
therefore, assist in the early diagnosis of pre-diabetes. This makes ultrasound a very valuable 
diagnostic tool to be used in the fight against type 2 diabetes mellitus. 
Non-alcoholic fatty liver is an important entity. It can cause direct liver injury as seen in the 
progression of the condition from simple steatosis through to NASH and cirrhosis. 
 NAFLD’s role in IR and as a precursor to type 2 Diabetes Mellitus is significant.  
There is a strong association between NAFLD and CVD. People with NAFLD have an 
increased likelihood of dying from CVD than the general population. The most common 
scenario for a patient with NAFLD is progression not to cirrhosis, but to death from 
cardiovascular disease [1]. 
Liver biopsy remains the gold standard for diagnosis of NAFLD; however, ultrasound can 
assist in the diagnostic process. If the condition is diagnosed early and accurately, 
interventions can be introduced to limit the progression of this disease and improve future 
patient outcomes. Cross-sectional and prospective data indicate that IR and obesity are two 
major modifiable risk factors for NAFLD [1]. 
Further research is needed to document the changes in liver texture and function that occur as 
a result of these interventions and to increase the confident use of ultrasound as a diagnostic 
tool for the future. 
Sonographers are in the unique position of being able to be involved in the diagnosis of this 
condition from the beginning. Ultrasound changes are apparent before effects are seen on 
blood tests and before there are clinical manifestations of disease.  If the condition is 
accurately documented and reported at this early stage, better health outcomes may result 
from early intervention which can have a huge beneficial impact for the many people 
suffering from NAFLD. 
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